ライフサイエンスコーパス: dexrazoxane

1 nge, 0 to 15.5 years), 132 died (67 received dexrazoxane).

2 randomly assigned to an arm with or without dexrazoxane.

3 gned patients to doxorubicin with or without dexrazoxane.

4 effect in the presence of the iron chelator dexrazoxane.

5 dose of doxorubicin preceded by 300 mg/m(2) dexrazoxane.

6 ved in patients randomly assigned to receive dexrazoxane.

7 l because of concerns of tumor protection by dexrazoxane.

8 21-0.93) but not for those who also received dexrazoxane (-0.41, -0.88 to 0.06; 0.15, -0.20 to 0.51).

9 Dexrazoxane: (1) The use of dexrazoxane is not routinely

10 In contrast, dexrazoxane (10 micromol/L), known clinically to limit a

11 n alone than in the 31 patients who received dexrazoxane (-2.03 v -0.24; P </= .001).

12 doses of doxorubicin 30 mg/m2/d for 2 days, dexrazoxane 300 mg/m2/d for 2 days, and cyclophosphamide

13 three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediate

14 hen combined with doxorubicin (60 mg/m2) and dexrazoxane (600 mg/m2), paclitaxel given as a 3-hour in

15 in (66 analysed) and 105 to doxorubicin plus dexrazoxane (68 analysed).

16 Dexrazoxane, a drug that attenuates doxorubicin-induced

17 Dexrazoxane, a free-radical scavenger, may protect the h

18 ntagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta,

19 Dexrazoxane also was not significantly associated with d

20 one were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T

21 up and 82 of 105 patients in the group given dexrazoxane and doxorubicin.

22 Dexrazoxane and Mito-T (4) ameliorated doxorubicin-induc

23 s were noted between the group that received dexrazoxane and the group that did not (P = .66).

24 port found an association between the use of dexrazoxane and the risk of developing secondary maligna

25 Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage t

26 We recommend dexrazoxane as a cardioprotectant for children and adole

27 Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dex

28 d not vary by dexrazoxane status (12.8% with dexrazoxane at 10 years v 12.2% without; hazard ratio [H

29 (4) The use of dexrazoxane can be considered in adult patients who have

30 ane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubic

31 To determine whether dexrazoxane decreases doxorubicin-associated injury of c

32 The dexrazoxane:doxorubicin dose ratio was 10:1, and the cum

33 Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during

34 Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxor

35 Dexrazoxane exerts greater long-term cardioprotective ef

36 ndom assignment to treatment with or without dexrazoxane given as a bolus infusion immediately before

37 (67-84) for children in the doxorubicin plus dexrazoxane group (p=0.99).

38 orubicin group and in 13% of the doxorubicin-dexrazoxane group before treatment but in 47% and 13%, r

39 up and in 92% of children in the doxorubicin-dexrazoxane group before treatment but in only 48% and 2

40 differ between groups: 76.7% (2.7%) for the dexrazoxane group versus 76.0% (2.7%) for the doxorubici

41 Dexrazoxane had no effect on the pharmacokinetics of pac

42 Dexrazoxane had no significant effect on the pharmacokin

43 otoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood.

44 ncluded topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187).

45 ng anticancer drugs, the catalytic inhibitor dexrazoxane (ICRF187) and mechanistic poison teniposide

46 results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis p

47 ated with doxorubicin and paclitaxel without dexrazoxane in other trials.

48 on which to base a guideline for the use of dexrazoxane in patients with cardiac risk factors or und

49 (3) The use of dexrazoxane in the adjuvant setting is not recommended o

50 evidence to make a guideline for the use of dexrazoxane in the treatment of pediatric malignancies,

51 Dexrazoxane is a drug used to prevent anthracycline-indu

52 Dexrazoxane is not recommended for routine use in breast

53 Dexrazoxane: (1) The use of dexrazoxane is not routinely recommended for patients wi

54 Dexrazoxane is the only cardioprotectant clinically appr

55 on with anthracycline-based chemotherapy and dexrazoxane, its therapeutic benefit remains uncertain.

56 (2) The use of dexrazoxane may be considered for patients with metastat

57 Given concerns that dexrazoxane may reduce treatment efficacy, induce second

58 clinical practice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are n

59 herapy- and radiotherapy-protectant activity-dexrazoxane, mesna, and amifostine-and questions about t

60 the clinical data regarding the activity of dexrazoxane, mesna, and amifostine.

61 orubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensifi

62 despite close monitoring and standard use of dexrazoxane, obliges a change in the dose and/or schedul

63 l be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years

64 e aimed to establish the long-term effect of dexrazoxane on the subclinical state of cardiac health i

65 nation with an established cardioprotectant, dexrazoxane, or a nitroxide conjugated to a triphenylpho

66 ies, eight occurred in patients who received dexrazoxane (P = .17).

67 Dexrazoxane prevents or reduces cardiac injury, as refle

68 Subgroup analysis showed dexrazoxane protection (p=0.04) for left ventricular fra

69 Similarly, subgroup analysis showed dexrazoxane protection (p=0.046) for the left ventricula

70 Dexrazoxane provides long-term cardioprotection from dox

71 Dexrazoxane provides long-term cardioprotection without

72 Dexrazoxane reduces cardiac damage during treatment with

73 The protective effect of dexrazoxane, relative to doxorubicin alone, on left vent

74 (6) Patients receiving dexrazoxane should continue to be monitored for cardiac

75 In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal

76 Overall mortality did not vary by dexrazoxane status (12.8% with dexrazoxane at 10 years v

77 mine overall and cause-specific mortality by dexrazoxane status.

78 s met the inclusion criteria: palifermin and dexrazoxane, three reports (two studies) each; amifostin

79 kemia or lymphoma, after extended follow-up, dexrazoxane use did not seem to compromise long-term sur

80 2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventricu

81 Dexrazoxane was administered with doxorubicin to minimiz

82 Dexrazoxane was cardioprotective and did not compromise

83 Dexrazoxane was given as an intravenous bolus before eac

84 The antiapoptotic action of dexrazoxane was mimicked by the superoxide-dismutase mim

85 Dexrazoxane was not associated with an increased risk of

86 Specifically, dexrazoxane was not associated with deaths from acute my

87 Dexrazoxane was started for total doxorubicin dose excee

88 Doxorubicin, cyclophosphamide, and dexrazoxane were administered on days 5 and 6 of the inf

89 Patients receiving dexrazoxane, which is cardioprotective for anthracycline

90 can be mitigated with the concomitant use of dexrazoxane with anthracycline.

91 Among 1,008 patients (507 received dexrazoxane) with a median follow-up of 12.6 years (rang

92 Dexrazoxane (Zinecard, also known as ICRF-187) has been